Myelofibrosis Clinical Trials
| Drug Name | JAK2 Inhibitor? | Company | Study Name | Timeline | Site Locations | For more information |
| * Ruxolitinib | Yes | Incyte, co-sponsored by Novartis | Study of the JAK Inhibitor Ruxolitinib | Opened March 2011; Est. completion March 2013 | Florida, Maryland, Texas |
Incyte Corporation Call Center at 855.463.3463 |
| * AB0024 | No | Gilead Sciences | A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adults With Myelofibrosis | Open June 2011; Est. completion February 2013 | Arizona, California, Texas |
Andrea Linder at alinder@stanford.edu Betsy Williams at betsyw@mdanderson.org Ruben Mesa at mesa.ruben@mayo.edu |
| *ICI-626 | No | Infinity Pharmaceuticals, Inc. | A Phase 2 Study with ICI-626 in Patients with MF | Started October 2011; Est. completion May 2013 |
Arizona, California, Texas |
AZ: Ruben Mesa at mesa.ruben@mayo.edu CA: Harshdeep Kaur at hkaur@stanford.edu TX: Sandra Rood at slrood@mdanderson.org |
| *Pomalidomide | No | Celgene | Study of Pomalidomide in Persons with Myelofibrosis (RESUME) | Opened August 2010; Est. Completion March 2017 | Click for a list of 81 worldwide trial sites |
Mary Bartlett at 913-266-0513 OR mbartlett@celgene.com Alyce Kay at 913-266-0369 OR akay@celgene.com |
| *Pomalidomide | No | University of Ulm | Pomalidomide in Patients with MPNs in Fibrotic Stage | Opened May 2009; Est. Completion September 2015 | Germany |
Richard Schlenk at richard.schlenk@uniklinik-ulm.de Frank Stegelmann at frank.stegelmann@uniklinik-ulm.de |
| *Oral Arsenic | Yes | Cephalon | Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults with Myelofibrosis | Opened April 2010; Est. completion June 2012 | New York | Roswell Park Cancer Institute: 877-275-7724 OR askrpci@roswellpark.org |
| *Panobinostat | No | Novartis | LBH589 (Pabinostat) for the Treatment of Myelofibrosis | Opened September 2009; Est. completion in December 2011 | New York |
Alice Mercado at alice.mercado@mssm.edu OR 212-241-4105
|
| * NS-018 | No | NS-Pharma, Inc. | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF | Opened June 2011; Est. completion June 2012 |
Arizona, Texas |
Srdan Vertosvesk at sverstov@mdanderson.org OR 713-745-3429 Ruben Mesa at mesa.ruben@mayo.edu OR 480-301-8335 |
| * CYT387 | Yes | YM BioSciences | Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-PV/ET Myelofibrosis | Opened August 2011; Est. completion in November 2012 | Arizona, Texas, Utah; Toronto, Montreal |
AZ: Ruben Mesa at mesa.ruben@mayo.edu TX: Srdan Verstovsek at sverstov@mdanderson.org ON: Vikas Gupta at vikas.gupta@uhn.ca Kate Sterling at ksterling@ymbiosciences.com OR 905-361-9493 |
| * INC424 | No | Novartis | Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF | Opened July 2011; Est. completion February 2016 | Japan, Korea, Taiwan |
Clinicaltrial.enquiries@novartis.com OR +41-61-324-1111 |
| *INC424 | No | Novartis | INC424 for Patients With Myelofibrosis (JUMP) | Argentina, Austria, Belgium, Brazil, Canada, Germany | Novartis Pharmaceuticals at +1-862-778-8300 | |
| *SAR302503 | No | Sanofi-Aventis | Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA) | Opened October 2011; Est. completion January 2016 | Kentucky, Minnesota, Ohio; Belgium, Italy, Sweden, United Kingdom | Contact-US@sanofi-aventis.com |
| * LY2784544 | Yes | Eli Lilly and Company | Study of LY2784544 Testing Alt. Dosing in Patients with MF | Opened April 2010; Est. completion July 2013 | Arizona, DC, Florida, New York, S. Carolina, Utah | 877-CTLILLY (877-285-4559) Mon-Fri from 9 AM to 5 PM EST |
| *Pegasys | No | Thomas Stauffer Larsen | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH) | Opened January 2012; Est. completion January 2020 | Denmark |
Thomas S. Larsen at thomas.stauffer.larsen@ouh.regionsyddanmark.dk Sally Grant at sally.grant@ouh.regionsyddanmark.dk |
|
TAK-901 |
No | Millennium Pharmaceuticals, Inc. | A Phase 1 Dose Escalation Study of TAK-901 in Subjects with Advanced Hematological Malignancies | Started March 2009; Established completion January 2012 | Michigan | Millennium Medical and Drug Info Center: 877-674-3784 OR medical@mlnm.com |
| Correlative Bio-Marker Study | n/a | MPD-RC | Correlative Biomarker Study in Patients with Myeloproliferative Disorders | D.C., Illinois, Maryland, New York, Utah; Bergamo and Florence, Italy; Gothenberg, Sweden |
Rona S. Weinberg, PhD 212-570-3412 OR rweinberg@nybloodcenter.org Ronald Hoffman, MD 212-241-2297 OR ronald.hoffman@mssm.edu |
|
| AZD1480 | Yes | AztraZeneca | Study to Assess the Safety of AZD1480 in Patients with Myeloproliferative Diseases (MF, post PV/ET MF) | Opened May 2009; Estimated completion November 2012 | New York, Texas; Villejuif, France | 800-236-9933 OR information.center@aztrazeneca.com |
| Lestaurtinib | Yes | MPD-RC | CEP-701 (Lestaurtinib) in Myelofibrosis | Opened April 2008, estimated completion in December 2012 | Utah, Illinois, New York, Pennsylvania, Ohio, Utah |
Dr. Elizabeth Hexner at 215-614-1847 Dr. Ron Hoffman at 212-241-2297 |
| Research Tissue Bank | n/a | MPD-RC | Study allows for the preservation and storage of a small portion of tissues to be used for the study of MPDs. | Opened September 2007; Estimated completion December 2011 | California, D.C., Illinois, Maryland, New York, Pennsylvania, Utah. Bergamo and Florence, Italy | Rona S. Weinberg, PhD 212-570-3412 OR rweinberg@nybloodcenter.org |
| Pegasys | No | Roche | Pegasys in Patients with Myeloproliferative Diseases | Opened April 2005; estimated completion December 2017 | Texas | Srdan Verstovsek at 713-745-3429 OR sverstov@mdanderson.org |
